Sarepta Therapeutics (SRPT) Current Deferred Revenue (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Current Deferred Revenue of $116.0 million for Q1 2026, up 158.67% year-over-year from $44.9 million in Q1 2025, and down 73.83% quarter-over-quarter from $443.4 million in Q4 2025.
Sarepta Therapeutics (SRPT) Current Deferred Revenue (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Current Deferred Revenue history runs 17 years deep, the most recent figure standing at $116.0 million for Q1 2026.
- In Q1 2026, Current Deferred Revenue rose 158.67% year-over-year to $116.0 million; the TTM figure through Mar 2026 stood at $116.0 million (up 158.67% YoY), while the FY2025 annual figure was $443.4 million, up 240.4% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $116.0 million, down from $443.4 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $485.4 million in Q3 2025, with the low at $22.5 million in Q3 2023.
- The 5-year median for Current Deferred Revenue is $89.2 million (2022), against an average of $148.2 million.
- The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue sank 74.79% in 2023, then soared 464.6% in 2024.
- Sarepta Therapeutics' Current Deferred Revenue stood at $89.2 million in 2022, then plunged by 43.51% to $50.4 million in 2023, then surged by 158.36% to $130.3 million in 2024, then surged by 240.4% to $443.4 million in 2025, then sank by 73.83% to $116.0 million in 2026.
- Business Quant data shows SRPT's Current Deferred Revenue at $116.0 million in Q1 2026, $443.4 million in Q4 2025, and $485.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 110.13 Mn |
| Mar 31, 2026 | 116.04 Mn |
| Dec 31, 2025 | 443.40 Mn |
| Sep 30, 2025 | 485.45 Mn |
| Jun 30, 2025 | 395.43 Mn |
| Mar 31, 2025 | 44.86 Mn |
| Dec 31, 2024 | 130.26 Mn |
| Sep 30, 2024 | 127.00 Mn |
| Jun 30, 2024 | 122.04 Mn |
| Mar 31, 2024 | 112.00 Mn |
| Dec 31, 2023 | 50.42 Mn |
| Sep 30, 2023 | 22.49 Mn |
| Jun 30, 2023 | 44.99 Mn |
| Mar 31, 2023 | 67.24 Mn |
| Dec 31, 2022 | 89.24 Mn |
| Sep 30, 2022 | 89.24 Mn |
| Jun 30, 2022 | 89.24 Mn |
| Mar 31, 2022 | 89.24 Mn |
| Dec 31, 2021 | 89.24 Mn |
| Sep 30, 2021 | 89.24 Mn |